Research programme: antiviral therapeutics - Spring Bank Pharmaceuticals

Drug Profile

Research programme: antiviral therapeutics - Spring Bank Pharmaceuticals

Alternative Names: Broad-spectrum antiviral - Spring Bank; RSV therapeutic - Spring Bank; SB 9400; SB 9941; SB 9946

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Nucleic acids; Small molecules
  • Mechanism of Action Immunomodulators; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Viral infections
  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 12 Sep 2016 Suspended - Preclinical for Viral infections in USA (PO) (Spring Bank Pharmaceuticals pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top